RU2120282C1 - Method of treatment of patients with the combined allergic skin and gastroenteric tract damages in children - Google Patents

Abstract

FIELD: medicine, pediatry. SUBSTANCE: invention relates to the combined atopic treatment of children with skin and gastroenteric tract damages. Method involves the use of food oil "Eiconol" at the dose 5-6 g per a day for course duration 1 month in combination with dietotherapy background. Method can be used in immunology and clinical allergology. EFFECT: enhanced effectiveness of method.

Description

 The method relates to medicine, in particular to children's allergology, and for the treatment of patients with combined lesions of the skin and gastrointestinal tract.

 A known method of treating patients with atopic dermatitis complicated by allergic sensitivity to house dust, pollen of plants and chronic gastritis. The treatment is carried out by conducting cytopheresis with the release of leukocyte cells, treating them with diuciphon, followed by reinfucing them to the patient. The specified procedure is carried out 2-3 times with an interval of 8-14 days.

 The disadvantage of this method of treatment is its duration and repeatedly occurring exacerbations of the disease.

 The prototype of the proposed method of treatment can be the use of H2 blockers in histological practice - histamine receptors, such suprastin, diphenhydramine, diazolin, etc., as well as calcium membrane channel blockers of immunocompetent cells (ketufen, sodium cromoline). However, the disadvantage of the above drugs is a number of side effects when they are used: the inability to take long courses without negative effects on the nervous system - drowsiness, distracted attention, decreased performance, discoordination; a negative effect on the coagulation system of the blood - a tendency to trobocytopenia; a negative effect on the skeletal system is the development of osteoporosis [1].

 The objective of the present invention is to increase the effectiveness of the treatment of allergic diseases in children, in particular combined allergic lesions of the skin and gastrointestinal tract, reducing treatment time and reducing the number of relapses of diseases.

 The problem is solved by the use of dietary oil Eikonol as a medicine in a dose of 5-6 g / day and a treatment course of 1 month.

 Edible oil "Akonol", the source of which is sea fish and fish products, is an oily liquid with a specific smell and taste of fish oil.

 The chemical composition of Eikonol is characterized by a balanced complex of biologically active factors, primarily the amount of polyunsaturated fatty acids (PUFAs) of the Omega-3 family, which have a significant effect on metabolism.

The content of fatty acids in Eikonol:
Saturated Fatty Acids (EFAs) - 30%
Monounsaturated Fatty Acids (MFAs) - 42%
Polyunsaturated Fatty Acids (PUFAs) - 28%
the ratio of PUFA Omega-6: Omega-3 is close to optimal and is equal to 1.0-3.0.

 It was established by experimental and clinical data that an increase in the dietary content of omega-3 PUFAs in the diet quickly affects the lipid composition of cell membranes, including platelet membranes, characterized by a decrease in the proportion of linoleic and arachidonic acids and an increase in the relative content of eicosapentaenoic (EPA) and docosahexaene (DHA) ) acids - (PUFA Omega-3). In turn, a decrease in arachidonic acid leads to a decrease in the formation of thromboxane A2, which does not possess aggational properties. Along with this, due to an increase in the level of Omega-3 PUFAs in membrane lipids, there is a potential possibility of enhancing the synthesis of E3 line ecozanoids, the physiological effects of which can be directly opposite to the action of ecozanoids, which are the product of the conversion of Omega-6 PUFAs.

 The addition of eicosapentaenoic and docosaenoic acids leads to their incorporation into the membrane phospholipids of cells and tissues. The presence of EPA in cells modulates inflammatory processes by reducing the inflammatory activity of cells to the induction of inflammatory mediators and the weakened inflammatory activity of newly formed inflammatory mediators. Studies in animal models of the late stage response to the allergen showed a similar histological picture in the respiratory tract and skin. In vitro dietary supplements have been shown to reduce the generation of leukotrienes and alter neutrophil function, inhibit zosinophil mobilization in the nosal challenge test, i.e. those cells that largely determine the late inflammatory response.

Clinical examples:
Example 1
Patient R., 10 years old
The diagnosis of allergic dermatitis, household sensitization. Allergic gastroduodenitis. Biliary dyskinesia of the hypomotor type.

 The girl was admitted to the clinic with complaints of skin itching, hyperthermia of the skin, escalation, pain and abdomen, not related to eating. During the examination, hypersensitivity to the house dust allergen was revealed. An intragastric test with the above allergen showed the presence of allergic gastroduodenitis. The course of treatment with house dust allergen (specific immunotherapy - SIT) caused a sharp exacerbation of the underlying disease. Due to the ineffectiveness of the therapy, the patient received a course of therapy with Eikonol edible oil at a dose of 5 g daily. Against the background of diet therapy, a significant improvement in the condition of the skin, the elimination of signs of inflammation, the disappearance of skin itching and abdominal pain was noted. Laboratory studies showed the disappearance of leukotriene B4 (before treatment, its level was 0.5) and a sharp decrease in the level of leukotriene C4 (before treatment, 10.88, after-6.35). The course of treatment was 1 month, clinical remission - 3 months.

 Example 2

 Patient D., 9 years old.

 Diagnosis: "allergic dermatitis; atopic asthma, interictal period; allergic gastroduodenitis. Sensitization to house dust."

 The boy was admitted to the hospital with complaints of periodic asthma attacks, skin itching, lichenification, skin hyperemia, escalation, pain in the epigastric and pyloroduodenal zones of the abdomen, not associated with food intake. During the examination, hypersensitivity to the house dust allergen was revealed. An intragastric test with the above allergen showed the presence of allergic gastroduodenitis. When conducting a course of specific immunotherapy with a house dust allergen, a sharp exacerbation of the underlying disease was noted: an attack of shortness of breath, increased skin itching. Due to the ineffectiveness of the therapy, the patient received a course of therapy with Eikonol edible oil at a dose of 6 g daily. Against the background of diet therapy, there was a lack of attacks of bronchial asthma, a significant improvement in the condition of the skin, the elimination of signs of inflammation, the disappearance of skin itching and abdominal pain. Laboratory studies showed a sharp decrease in C4 leukotriene (before treatment, 18.35, after-5.86). The course of treatment was 1 month, clinical remission-2 months.

 A treatment course for combined allergic skin and gastrointestinal lesions was carried out for 34 patients aged 7 to 14 using Eikonol edible oil in the form of 0.25 g capsules at a dose of 5-6 g / day for a month. Against the background of the ongoing diet therapy, in the complex of which Eikonol oil was included, 29 children had a more pronounced therapeutic effect from the treatment as compared to the patients in the control group: skin itching, hyperemia of the skin, escortia, and abdominal pain disappeared much faster dispensary phenomena, epiteoization came faster; the skin acquired a soft, elastic character. In addition to clinical data, the effectiveness of the therapy was confirmed by laboratory tests. The in vitro release of leukotrienes from peripheral blood leukocytes of patients with combined lesions of the skin and gastrointestinal tract was carried out under the influence of platelet activation factor (FAT). Leukotrienes play an important role as mediators of inflammation and, in particular, inflammation of an allergic nature. It was shown that preincubation of leukocytes for 40 minutes leads to blocking the release of leukotrienes from the cells. It was found that the effect of Eikonol on the leukocytes of patients in vitro causes a significant decrease in the release of C4 leukotrienes from 10.18 + 2.61 ng / 10 to 4.25 + 1 in a group of children with a combination of atopic skin lesions and gastrointestinal tract with FAT stimulation. 4 ng / 10, n = 8, p <0.02.

Claims (1)

 A method of treating combined allergic lesions of the skin and the gastrointestinal tract in children by administering drugs, characterized in that, against the background of diet therapy, Eikonol edible oil is used as a drug in a dose of 5-6 g / day with a treatment course of 1 month.